Thrombopoietic cytokines and platelet count in multiple myeloma

ÖZKURT Z. N., Yagci M., Sucak G. T., Kirazli S., HAZNEDAR R.

PLATELETS, vol.21, no.1, pp.33-36, 2010 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 1
  • Publication Date: 2010
  • Doi Number: 10.3109/09537100903360007
  • Journal Name: PLATELETS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.33-36
  • Hacettepe University Affiliated: Yes


Cytokines like interleukin (IL)-6 and IL-1 beta are both implicated in multiple mycloma (MM) pathogenesis and megakaryopoiesis. The dynamic interaction between thrombopoiesis and thrombopoietic cytokines in MM may affect platelet (PLT) counts. Sixty-eight patients with MM (30 female, 38 male, median age 58 (40-79), 38 newly diagnosed, 15 in plateau, and 15 relapse and/or refractory patients) and 21 controls were included in the study. Plasma levels of thrombopotein (TPO), IL-1 beta, IL-11 and IL-6 were measured by ELISA. PLT counts were not different between the control group and MM patients with various disease stages and activity IL-6 and TPO levels were higher in MM patients than healthy subjects (p < 0 001). PLT counts were inversely correlated with TPO (r= -0.566, p < 0 001) and positively correlated with IL-6 (r=0.263,- p=0.04) levels in MM patients. TPO and IL-6 levels were significantly correlated (r= 0.305, p < 0 001). Disease activity has no effect on plasma cytokinc levels. TPO levels were higher in stage III than stage I (p = 0.05) and stage II (p = 0.03) patients in newly diagnosed MM. High TPO levels induced by IL-6 may sustain normal PLT counts despite bone marrow infiltration by plasma cells and decreased PLT half-life.